Funding and going-concern risk
The company states it will require additional funding to finance growth and strategic objectives.
- Scope
- Corporate-wide
- Materiality
- high
Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. is a U.S.-based regenerative medicine company centered on stem cell-related products, clinical services, practitioner education, and manufacturing support. Its business combines direct patient treatments, product commercialization, training programs, and clinic-network operations across international markets.
−11,5 %
55,1 %
−153,2 %
+24,2 %
0.03
0.03
| % | |
|---|---|
| Regenerative medicine products | 40% Cell therapy kits, exosome therapies, peptides, biologics, and related consumables sold to clinics and practitioners. |
| Clinical treatment services | 30% Direct patient care and treatment procedures delivered through company-operated or affiliated clinics. |
| Education and certification | 15% Training, seminars, congresses, and practitioner certification through the ISSCA platform. |
| Distribution and support services | 10% Logistics, inventory management, technical support, and sales training for external partners and clinics. |
| Manufacturing and development | 5% Manufacturing scale-up and product development for new regenerative medicine formulations. |
The company sells to medical practitioners, clinics, and external distribution partners that use or resell regenerative...
- Medical practitioners and clinicsprimary
Buy stem cell kits, products, equipment, and training to deliver regenerative medicine protocols.
- Direct patient care customersprimary
Patients receiving treatments at company clinics, generating service revenue and product pull-through.
- External distribution partnerssecondary
Qualified partners that market and distribute the company's products in their territories.
- Education and certification participantssecondary
Practitioners and institutions that attend ISSCA programs, seminars, and certification courses.
- Medical institutions and research collaboratorsemerging
Universities and clinical organizations engaged for protocol development and validation.
The company operates internationally, with clinical and distribution activity spanning the Americas, the Middle East,...
- •Clinic operations in Cancun, Mexico
- •Clinic presence in Dubai, United Arab Emirates
- •Planned expansion into Puerto Rico and Argentina
- •Potential entry into Saudi Arabia
- •U.S. market development tied to regulatory progress
The company is building a vertically integrated regenerative medicine platform that combines product development,...
01
Clinic network expansionshort-term
Direct patient care adds recurring revenue and creates demand for the company's products.
02
Manufacturing scale-upshort-term
Greater production capacity supports product availability, quality control, and vertical integration.
03
Product diversificationmedium-term
New formulations broaden the addressable market and reduce reliance on a narrow product set.
04
Education platform expansionmedium-term
Training and certification support practitioner adoption and reinforce the company's protocol ecosystem.
05
U.S. market entrymedium-term
The U.S. offers a large market but requires careful regulatory navigation and clinical credibility.
The business depends on regulatory acceptance of regenerative medicine, clinical adoption, and the ability to fund...
Regulatory risk in regenerative medicine
Clinical use of stem cell and related therapies depends on evolving rules and approvals in each market.
- Scope
- U.S., Mexico, UAE, and other expansion markets
- Materiality
- high
Execution risk in clinic expansion
New clinics require local infrastructure, staffing, compliance, and patient demand to succeed.
- Scope
- Puerto Rico, Argentina, Saudi Arabia, U.S.
- Materiality
- high
Manufacturing and quality control risk
Scaling production across locations can affect product consistency and regulatory compliance.
- Scope
- Manufacturing footprint
- Materiality
- high
Reputation and clinical outcome risk
Patient-facing regenerative therapies are sensitive to safety, efficacy, and practitioner trust.
- Scope
- Clinic network and education platform
- Materiality
- high
ASC 606 revenue recognition
Product shipments and treatment sessions may be recognized in different periods
Goodwill and acquisition accounting
Could create non-cash charges if acquired value declines
Derivative liability valuation
May introduce volatility in reported results
Going-concern assessment
Affects balance sheet presentation and investor risk assessment
Fair value estimates
Can materially affect reported equity and expenses
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZ · Biological Products, (No Diagnostic Substances)
Harvard Apparatus Regenerative Technology, Inc.
HRGN · Surgical & Medical Instruments & Apparatus
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
MIMEDX GROUP, INC.
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
REGENEREX PHARMA, INC.
Pharmaceutical Preparations
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
: 29.4.2026